Buddlejasaponin IV

CAS No. 139523-30-1

Buddlejasaponin IV( —— )

Catalog No. M30940 CAS No. 139523-30-1

Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 459 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Buddlejasaponin IV
  • Note
    Research use only, not for human use.
  • Brief Description
    Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation.
  • Description
    Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation.
  • In Vitro
    Buddlejasaponin IV induces cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes.Buddlejasaponin IV (BS-IV) exhibits anti-inflammatory effect of through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-κB inactivation.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    139523-30-1
  • Formula Weight
    943.12
  • Molecular Formula
    C48H78O18
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • CRANAD-28

    CRANAD-28 can mark plaques and cerebral amyloid angiopathy.

  • CB-6644

    CB-6644 is a selective inhibitor of the RUVBL1/2 complex and blocks the ATPase activity of RUVBL1/2 (IC50 = 15 nM).

  • TriGalNAc CBz

    TriGalNAc CBz is a GalNAc derivative. As an ASGPR ligand, tri-GalNAc targets lysosomes in mRNA drug delivery and LYTAC studies.L-DABA hydrobromide.